ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications
- Authors
- Jin, Wook
- Issue Date
- Jul-2020
- Publisher
- MDPI
- Keywords
- Epidermal growth factor receptor (EGFR) family; cholangiocarcinoma; aggressiveness; mutation; chemoresistance; EGFR family-targeting inhibitors
- Citation
- JOURNAL OF CLINICAL MEDICINE, v.9, no.7
- Journal Title
- JOURNAL OF CLINICAL MEDICINE
- Volume
- 9
- Number
- 7
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78033
- DOI
- 10.3390/jcm9072255
- ISSN
- 2077-0383
- Abstract
- The erythroblastic leukemia viral oncogene homolog (ErBb) family consists of the receptor tyrosine kinases (RTK) epidermal growth factor receptor (EGFR; also called ERBB1), ERBB2, ERBB3, and ERBB4. This family is closely associated with the progression of cholangiocarcinoma (CC) through the regulation of cellular networks, which are enhanced during tumorigenesis, metastasis, and chemoresistance. Additionally, the constitutive activation of cellular signaling by the overexpression and somatic mutation-mediated alterations conferred by the ErBb family on cholangiocarcinoma and other cancers enhances tumor aggressiveness and chemoresistance by contributing to the tumor microenvironment. This review summarizes the recent findings on the molecular functions of the ErBb family and their mutations during the progression of cholangiocarcinoma. It also discusses the developments and applications of various devising strategies for targeting the ErBb family through different inhibitors in various stages of clinical trials, which are essential for improving targeted clinical therapies.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78033)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.